The Worst Mistake Moderna Investors Can Make in 2022
Moderna (NASDAQ: MRNA) has come a long way in just two years. The biotech company developed one of the leading coronavirus vaccines in about nine months -- and has since made billions of dollars in vaccine revenue and profit. And over that time period, the stock soared more than 1,200%.
Sounds like a biotech success story, right? It is. But every story comes with some bumps along the way. And Moderna may be in that chapter right now. The stock has dropped more than 60% from its peak back in August. And these days Moderna investors may be wondering whether they should stay around for the rest of the story. Of course, the decision depends on each individual's goals and investment horizon. Still, there is one particular thing Moderna investors should avoid in 2022.
Image source: Getty Images.
Source Fool.com
